These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 11507210)

  • 1. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses.
    Leen A; Meij P; Redchenko I; Middeldorp J; Bloemena E; Rickinson A; Blake N
    J Virol; 2001 Sep; 75(18):8649-59. PubMed ID: 11507210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and prevalence of CD8(+) T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2.
    Meij P; Leen A; Rickinson AB; Verkoeijen S; Vervoort MB; Bloemena E; Middeldorp JM
    Int J Cancer; 2002 May; 99(1):93-9. PubMed ID: 11948498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis.
    Lünemann JD; Edwards N; Muraro PA; Hayashi S; Cohen JI; Münz C; Martin R
    Brain; 2006 Jun; 129(Pt 6):1493-506. PubMed ID: 16569670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma.
    Taylor GS; Haigh TA; Gudgeon NH; Phelps RJ; Lee SP; Steven NM; Rickinson AB
    J Virol; 2004 Jan; 78(2):768-78. PubMed ID: 14694109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
    Nowakowska J; Stuehler C; Egli A; Battegay M; Rauser G; Bantug GR; Brander C; Hess C; Khanna N
    Cytotherapy; 2015 Sep; 17(9):1280-91. PubMed ID: 26276009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4 and CD8 T cell responses to tumour-associated Epstein-Barr virus antigens in nasopharyngeal carcinoma patients.
    Lin X; Gudgeon NH; Hui EP; Jia H; Qun X; Taylor GS; Barnardo MC; Lin CK; Rickinson AB; Chan AT
    Cancer Immunol Immunother; 2008 Jul; 57(7):963-75. PubMed ID: 18094968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.
    Kalra M; Gerdemann U; Luu JD; Ngo MC; Leen AM; Louis CU; Rooney CM; Gottschalk S
    Cytotherapy; 2019 Feb; 21(2):212-223. PubMed ID: 30396848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining the expression hierarchy of latent T-cell epitopes in Epstein-Barr virus infection with TCR-like antibodies.
    Sim AC; Too CT; Oo MZ; Lai J; Eio MY; Song Z; Srinivasan N; Tan DA; Pang SW; Gan SU; Lee KO; Loh TK; Chen J; Chan SH; MacAry PA
    Sci Rep; 2013 Nov; 3():3232. PubMed ID: 24240815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term carriers generate Epstein-Barr virus (EBV)-specific CD4(+) and CD8(+) polyfunctional T-cell responses which show immunodominance hierarchies of EBV proteins.
    Ning RJ; Xu XQ; Chan KH; Chiang AK
    Immunology; 2011 Oct; 134(2):161-71. PubMed ID: 21896011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.
    Tan LC; Mowat AG; Fazou C; Rostron T; Roskell H; Dunbar PR; Tournay C; Romagné F; Peyrat MA; Houssaint E; Bonneville M; Rickinson AB; McMichael AJ; Callan MF
    Arthritis Res; 2000; 2(2):154-64. PubMed ID: 11062606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer.
    Taylor GS; Jia H; Harrington K; Lee LW; Turner J; Ladell K; Price DA; Tanday M; Matthews J; Roberts C; Edwards C; McGuigan L; Hartley A; Wilson S; Hui EP; Chan AT; Rickinson AB; Steven NM
    Clin Cancer Res; 2014 Oct; 20(19):5009-22. PubMed ID: 25124688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.
    Khanna R; Burrows SR; Nicholls J; Poulsen LM
    Eur J Immunol; 1998 Feb; 28(2):451-8. PubMed ID: 9521052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of Epstein-Barr virus-specific memory CD4+ T cells using a peptide-based cultured enzyme-linked immunospot assay.
    Calarota SA; Chiesa A; Zelini P; Comolli G; Minoli L; Baldanti F
    Immunology; 2013 Aug; 139(4):533-44. PubMed ID: 23560877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MHC II tetramers visualize human CD4+ T cell responses to Epstein-Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 response.
    Long HM; Chagoury OL; Leese AM; Ryan GB; James E; Morton LT; Abbott RJ; Sabbah S; Kwok W; Rickinson AB
    J Exp Med; 2013 May; 210(5):933-49. PubMed ID: 23569328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reconstitution of EBV latent but not lytic antigen-specific CD4+ and CD8+ T cells after HIV treatment with highly active antiretroviral therapy.
    Piriou E; Jansen CA; van Dort K; De Cuyper I; Nanlohy NM; Lange JM; van Oers MH; Miedema F; van Baarle D
    J Immunol; 2005 Aug; 175(3):2010-7. PubMed ID: 16034146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.
    Münz C; Bickham KL; Subklewe M; Tsang ML; Chahroudi A; Kurilla MG; Zhang D; O'Donnell M; Steinman RM
    J Exp Med; 2000 May; 191(10):1649-60. PubMed ID: 10811859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.
    Perez EM; Foley J; Tison T; Silva R; Ogembo JG
    Oncotarget; 2017 Mar; 8(12):19255-19273. PubMed ID: 27926486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type 2 cytokines predominate in the human CD4(+) T-lymphocyte response to Epstein-Barr virus nuclear antigen 1.
    Steigerwald-Mullen P; Kurilla MG; Braciale TJ
    J Virol; 2000 Aug; 74(15):6748-59. PubMed ID: 10888613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic T-lymphocyte responses to a polymorphic Epstein-Barr virus epitope identify healthy carriers with coresident viral strains.
    Brooks JM; Croom-Carter DS; Leese AM; Tierney RJ; Habeshaw G; Rickinson AB
    J Virol; 2000 Feb; 74(4):1801-9. PubMed ID: 10644353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of a HLA II promiscuous peptide cocktail as potential vaccine against EBV latency II malignancies.
    Depil S; Moralès O; Castelli FA; Delhem N; François V; Georges B; Dufossé F; Morschhauser F; Hammer J; Maillère B; Auriault C; Pancré V
    J Immunother; 2007; 30(2):215-26. PubMed ID: 17471168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.